GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (NAS:ALBO) » Definitions » E10

Albireo Pharma (Albireo Pharma) E10 : $-14.78 (As of Sep. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Albireo Pharma's adjusted earnings per share data for the three months ended in Sep. 2022 was $-1.920. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-14.78 for the trailing ten years ended in Sep. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-04-28), Albireo Pharma's current stock price is $44.15. Albireo Pharma's E10 for the quarter that ended in Sep. 2022 was $-14.78. Albireo Pharma's Shiller PE Ratio of today is .


Albireo Pharma E10 Historical Data

The historical data trend for Albireo Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma E10 Chart

Albireo Pharma Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -86.92 -63.51 -38.65 -20.95 -18.54

Albireo Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.90 -18.54 -17.64 -16.37 -14.78

Competitive Comparison of Albireo Pharma's E10

For the Biotechnology subindustry, Albireo Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albireo Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albireo Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Albireo Pharma's Shiller PE Ratio falls into.



Albireo Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Albireo Pharma's adjusted earnings per share data for the three months ended in Sep. 2022 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=-1.92/125.2265*125.2265
=-1.920

Current CPI (Sep. 2022) = 125.2265.

Albireo Pharma Quarterly Data

per share eps CPI Adj_EPS
201212 -7.800 96.871 -10.083
201303 -11.100 98.209 -14.154
201306 -19.800 98.518 -25.168
201309 1.500 98.790 1.901
201312 -3.600 98.326 -4.585
201403 -8.700 99.695 -10.928
201406 -4.500 100.560 -5.604
201409 -3.000 100.428 -3.741
201412 -6.000 99.070 -7.584
201503 -5.400 99.621 -6.788
201506 -3.600 100.684 -4.478
201509 -1.560 100.392 -1.946
201512 -1.500 99.792 -1.882
201603 -2.700 100.470 -3.365
201606 -1.500 101.688 -1.847
201609 -0.750 101.861 -0.922
201612 -13.190 101.863 -16.215
201703 -1.060 102.862 -1.290
201706 -0.860 103.349 -1.042
201709 -0.730 104.136 -0.878
201712 -0.520 104.011 -0.626
201803 -0.150 105.290 -0.178
201806 -1.220 106.317 -1.437
201809 -1.170 106.507 -1.376
201812 -1.340 105.998 -1.583
201903 -1.390 107.251 -1.623
201906 -1.350 108.070 -1.564
201909 -1.730 108.329 -2.000
201912 -0.570 108.420 -0.658
202003 -2.230 108.902 -2.564
202006 -1.380 108.767 -1.589
202009 -1.960 109.815 -2.235
202012 -1.300 109.897 -1.481
202103 -2.290 111.754 -2.566
202106 -1.900 114.631 -2.076
202109 2.900 115.734 3.138
202112 -0.570 117.630 -0.607
202203 -2.190 121.301 -2.261
202206 -2.040 125.017 -2.043
202209 -1.920 125.227 -1.920

Add all the adjusted EPS together and divide 10 will get our e10.


Albireo Pharma  (NAS:ALBO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Albireo Pharma E10 Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Albireo Pharma (Albireo Pharma) Business Description

Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.
Executives
Harford Simon N.r. officer: CFO and Treasurer AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Pamela Stephenson officer: Chief Commercial Officer C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Martha J. Carter officer: Chief Regulatory Officer C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Jan Mattsson officer: Chief Operating Officer C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109
Cooper Ronald Harold Wilfred director, officer: President and CEO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Michelle Graham officer: Chief Human Resources Officer 10000 WEHRLE DRIVE, CLARENCE NY 14031
Jason Duncan officer: General Counsel C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Paul Streck officer: Chief Medical Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Craig C. Hopkinson director 852 WINTER STREET, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Susan Alesina director C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON MA 02109
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Patrick Taylor Horn officer: Chief Medical Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

Albireo Pharma (Albireo Pharma) Headlines

From GuruFocus

Moore Kuehn Encourages ALBO, LPTX, ALR, and CEMI Investors to Contact Law Firm

By Stock market mentor Stock market mentor 02-08-2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALBO, AJRD, CBIO, STAR

By Stock market mentor Stock market mentor 02-03-2023